ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Cambridge, Mass.-based biotech firm Verastem has paid Pfizer an undisclosed sum for rights to PF-04554878, a focal adhesion kinase (FAK) inhibitor that has completed Phase I studies. Verastem has two other FAK inhibitors under development but says the Pfizer deal gives it a “Phase II-ready” drug candidate. In a separate deal, Verastem is collaborating with Eisai to develop small-molecule inhibitors of Wnt, a protein network involved in the development of cancer stem cells. Verastem and Eisai will jointly develop analogs of Verastem’s existing Wnt inhibitor, VS-507.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X